Published in Neuropsychopharmacology on April 29, 2013
Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence. Mol Psychiatry (2013) 0.87
Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors. J Pharmacol Exp Ther (2014) 0.82
Dissociation of tolerance and nicotine withdrawal-associated deficits in contextual fear. Brain Res (2014) 0.79
Contributions of β2 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice. Psychopharmacology (Berl) (2014) 0.78
Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). Neuropharmacology (2015) 0.77
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors. J Med Chem (2014) 0.77
Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies. J Clin Pharm Ther (2014) 0.76
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation. Front Mol Neurosci (2015) 0.75
Thyroid hormone signaling: Contribution to neural function, cognition, and relationship to nicotine. Neurosci Biobehav Rev (2015) 0.75
Distinct Roles of CREB within the Ventral and Dorsal Hippocampus in Mediating Nicotine Withdrawal Phenotypes. Neuropsychopharmacology (2016) 0.75
Withdrawal From Chronic Nicotine Reduces Thyroid Hormone Levels and Levothyroxine Treatment Ameliorates Nicotine Withdrawal-Induced Deficits in Hippocampus-Dependent Learning in C57BL/6J Mice. Nicotine Tob Res (2014) 0.75
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (2003) 16.14
Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med (2000) 12.83
Cigarette smoking among adults--United States, 2006. MMWR Morb Mortal Wkly Rep (2007) 8.14
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem (2005) 6.13
MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry (1995) 5.34
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA (2006) 5.19
Regional dissociations within the hippocampus--memory and anxiety. Neurosci Biobehav Rev (2004) 4.44
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology (2006) 3.93
Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) (2005) 3.92
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) (1992) 2.97
Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res (1994) 2.95
Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry (2009) 2.94
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol (2009) 2.90
It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol (2007) 2.85
Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci (2001) 2.77
Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci (2005) 2.59
Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry (2006) 2.53
Hippocampal volume in women victimized by childhood sexual abuse. Psychol Med (1997) 2.52
Cognitive effects of nicotine. Biol Psychiatry (2001) 2.41
Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev (2005) 2.40
Sex differences and opposite effects of stress on dendritic spine density in the male versus female hippocampus. J Neurosci (2001) 2.37
Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat Neurosci (2010) 2.30
Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport (2002) 2.28
Ventral hippocampal lesions affect anxiety but not spatial learning. Behav Brain Res (2003) 2.12
Amygdala and ventral hippocampus contribute differentially to mechanisms of fear and anxiety. Behav Neurosci (2004) 2.09
Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther (2008) 2.04
Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther (1983) 2.03
Microdialysis measurement of cortical and hippocampal acetylcholine release during sleep-wake cycle in freely moving cats. Brain Res (1995) 1.90
Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. Neuropsychopharmacology (2007) 1.83
Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science (1983) 1.78
Double dissociation of function within the hippocampus: spatial memory and hyponeophagia. Behav Neurosci (2002) 1.72
Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol (2008) 1.71
Nicotine dependence, depression, and gender: characterizing phenotypes based on withdrawal discomfort, response to smoking, and ability to abstain. Nicotine Tob Res (2005) 1.70
Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol (2006) 1.62
Hippocampal CA1 circuitry dynamically gates direct cortical inputs preferentially at theta frequencies. J Neurosci (2005) 1.62
Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. Addiction (2010) 1.60
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol (2010) 1.59
Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Hum Psychopharmacol (2001) 1.58
Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci (2011) 1.55
The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells. J Pharmacol Exp Ther (2004) 1.53
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors. Mol Pharmacol (2008) 1.48
Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. J Neurosci (2007) 1.48
Effects of chronic stress on structure and cell function in rat hippocampus and hypothalamus. Stress (2004) 1.46
The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. J Pharmacol Exp Ther (2009) 1.45
Nicotine withdrawal increases threat-induced anxiety but not fear: neuroadaptation in human addiction. Biol Psychiatry (2010) 1.41
Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psychiatry (2003) 1.31
A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur J Pharmacol (2006) 1.29
Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci (2010) 1.28
Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol Pharmacol (1995) 1.28
Validation of a simple, ethologically relevant paradigm for assessing anxiety in mice. Biol Psychiatry (2003) 1.24
Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther (2009) 1.24
Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior. J Pharmacol Exp Ther (2010) 1.24
The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) (2009) 1.24
cAMP response element-binding protein deficiency allows for increased neurogenesis and a rapid onset of antidepressant response. J Neurosci (2007) 1.23
Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology (2008) 1.20
Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology (Berl) (2010) 1.20
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol (2009) 1.19
Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380. Psychopharmacology (Berl) (2011) 1.14
The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav (1989) 1.13
Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. Nicotine Tob Res (2010) 1.13
Anxiety is functionally segregated within the septo-hippocampal system. Brain Res (2004) 1.10
The neuropsychology of anxiety: reprise. Nebr Symp Motiv (1996) 1.09
Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression. ChemMedChem (2009) 1.09
Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav Neurosci (2008) 1.07
Nicotinic excitatory postsynaptic potentials in hippocampal CA1 interneurons are predominantly mediated by nicotinic receptors that contain α4 and β2 subunits. Neuropharmacology (2011) 1.07
Brain tissue oxygen amperometry in behaving rats demonstrates functional dissociation of dorsal and ventral hippocampus during spatial processing and anxiety. Eur J Neurosci (2010) 1.06
Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. Psychopharmacology (Berl) (2011) 1.02
Stress-induced changes in hippocampal function. Prog Brain Res (2008) 1.02
Anxiety and hippocampus volume in the rat. Neuropsychopharmacology (2006) 1.00
Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacol Biochem Behav (2001) 1.00
Magnetic resonance imaging studies of cigarette smoking. Handb Exp Pharmacol (2009) 1.00
Human functional neuroimaging in nicotine and tobacco research: basics, background, and beyond. Nicotine Tob Res (2004) 0.99
Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. J Pharmacol Exp Ther (2012) 0.99
Dopamine signaling through D1-like versus D2-like receptors in the nucleus accumbens core versus shell differentially modulates nicotine reward sensitivity. J Neurosci (2008) 0.98
The effects of acute, chronic, and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice. Psychopharmacology (Berl) (2011) 0.97
Hippocampal nAChRs mediate nicotine withdrawal-related learning deficits. Eur Neuropsychopharmacol (2009) 0.96
Overlapping and distinct brain regions associated with the anxiolytic effects of chlordiazepoxide and chronic fluoxetine. Neuropsychopharmacology (2007) 0.95
Subregional hippocampal deformations in major depressive disorder. J Affect Disord (2010) 0.94
Hippocampal and striatal gray matter volume are associated with a smoking cessation treatment outcome: results of an exploratory voxel-based morphometric analysis. Psychopharmacology (Berl) (2010) 0.94
Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. Proc Natl Acad Sci U S A (2012) 0.94
Nicotinic receptors in the dorsal and ventral hippocampus differentially modulate contextual fear conditioning. Hippocampus (2012) 0.93
Transient and persistent consequences of acute stress on long-term potentiation (LTP), synaptic efficacy, theta rhythms and bursts in area CA1 of the hippocampus. Synapse (1997) 0.92
Mild anxiogenic effects of nicotine withdrawal in mice. Eur J Pharmacol (2005) 0.92
Reversible inactivation of the entorhinal cortex disrupts the establishment and expression of latent inhibition of cued fear conditioning in C57BL/6 mice. Hippocampus (2007) 0.92
Anxiolytic effect of serotonin depletion in the novelty-induced hypophagia test. Psychopharmacology (Berl) (2006) 0.91
A longer course of varenicline therapy improves smoking cessation rates. Prev Cardiol (2008) 0.91
Genetic background influences the effects of withdrawal from chronic nicotine on learning and high-affinity nicotinic acetylcholine receptor binding in the dorsal and ventral hippocampus. Psychopharmacology (Berl) (2012) 0.90
Functional amygdala-hippocampus connectivity during anticipation of aversive events is associated with Gray's trait "sensitivity to punishment". Biol Psychiatry (2010) 0.88
α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties. Behav Pharmacol (2011) 0.88
Low dose nicotine and antagonism of β2 subunit containing nicotinic acetylcholine receptors have similar effects on affective behavior in mice. PLoS One (2012) 0.88
Stressful experience has opposite effects on dendritic spines in the hippocampus of cycling versus masculinized females. Neurosci Lett (2008) 0.87
Effects of pyridine ring substitutions on affinity, efficacy, and subtype selectivity of neuronal nicotinic receptor agonist epibatidine. J Pharmacol Exp Ther (2002) 0.86
Running-induced anxiety is dependent on increases in hippocampal neurogenesis. Genes Brain Behav (2012) 0.86
Pharmacological and toxicological evaluation of 2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a ligand for imaging cerebral nicotinic acetylcholine receptors with positron emission tomography. J Pharmacol Exp Ther (2004) 0.85
Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair. Psychopharmacology (Berl) (2012) 0.84
Septal GABAergic and hippocampal cholinergic systems interact in the modulation of anxiety. Neuroscience (2003) 0.84
Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology (Berl) (2013) 0.83
Short- and long-lasting consequences of in vivo nicotine treatment on hippocampal excitability. J Neurosci (2011) 0.82
Disrupted dentate granule cell chloride regulation enhances synaptic excitability during development of temporal lobe epilepsy. J Neurosci (2007) 2.00
Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A (2009) 1.76
cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci (2002) 1.71
Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol (2008) 1.71
Massive and specific dysregulation of direct cortical input to the hippocampus in temporal lobe epilepsy. J Neurosci (2006) 1.71
Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J Neurosci (2005) 1.68
Hippocampal CA1 circuitry dynamically gates direct cortical inputs preferentially at theta frequencies. J Neurosci (2005) 1.62
cAMP response element-binding protein is required for stress but not cocaine-induced reinstatement. J Neurosci (2004) 1.59
OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend (2010) 1.55
Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat Neurosci (2011) 1.53
Dynamic regulation of synaptic GABA release by the glutamate-glutamine cycle in hippocampal area CA1. J Neurosci (2006) 1.52
Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. J Neurosci (2007) 1.48
Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron (2005) 1.45
Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci (2008) 1.41
The effects of DHBE and MLA on nicotine-induced enhancement of contextual fear conditioning in C57BL/6 mice. Psychopharmacology (Berl) (2005) 1.39
Genetic evidence for a role of CREB in sustained cortical arousal. J Neurophysiol (2003) 1.37
Functional regulation of the dentate gyrus by GABA-mediated inhibition. Prog Brain Res (2007) 1.37
Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology (Berl) (2005) 1.37
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29
Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci (2005) 1.24
Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior. J Pharmacol Exp Ther (2010) 1.24
cAMP response element-binding protein deficiency allows for increased neurogenesis and a rapid onset of antidepressant response. J Neurosci (2007) 1.23
The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res (2011) 1.18
Beta2 subunit containing acetylcholine receptors mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning. Neurobiol Learn Mem (2007) 1.16
Endocrine and gene expression changes following forced swim stress exposure during cocaine abstinence in mice. Psychopharmacology (Berl) (2008) 1.14
Hippocampal microcircuit dynamics probed using optical imaging approaches. J Physiol (2011) 1.14
Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res (2008) 1.14
Nicotine enhances both foreground and background contextual fear conditioning. Neurosci Lett (2005) 1.13
Making a bad thing worse: adverse effects of stress on drug addiction. J Clin Invest (2008) 1.13
Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. Nicotine Tob Res (2010) 1.13
Activating transcription factor 1 and CREB are important for cell survival during early mouse development. Mol Cell Biol (2002) 1.11
Molecular and genetic substrates linking stress and addiction. Brain Res (2009) 1.11
beta2 subunit-containing nicotinic receptors mediate the enhancing effect of nicotine on trace cued fear conditioning in C57BL/6 mice. Psychopharmacology (Berl) (2006) 1.11
Nicotine enhances context learning but not context-shock associative learning. Behav Neurosci (2008) 1.09
NAC1 regulates the recruitment of the proteasome complex into dendritic spines. J Neurosci (2007) 1.08
Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav Neurosci (2008) 1.07
2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter. J Pharmacol Exp Ther (2014) 1.07
Effects of the histone deacetylase inhibitor sodium butyrate in models of depression and anxiety. Neuropharmacology (2009) 1.06
Ventral tegmental afferents in stress-induced reinstatement: the role of cAMP response element-binding protein. J Neurosci (2010) 1.06
A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. Biochem J (2012) 1.06
Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Behav Genet (2011) 1.03
Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. Behav Cogn Neurosci Rev (2002) 1.02
Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc Natl Acad Sci U S A (2012) 1.02
Developmental effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Neurobiol Learn Mem (2012) 1.01
Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. J Pharmacol Exp Ther (2012) 0.99
Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology (2006) 0.99
Stress-induced potentiation of cocaine reward: a role for CRF R1 and CREB. Neuropsychopharmacology (2009) 0.99
Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacol Biochem Behav (2007) 0.99
Interactive effects of ethanol and nicotine on learning in C57BL/6J mice depend on both dose and duration of treatment. Psychopharmacology (Berl) (2007) 0.99
Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors. Neuropharmacology (2010) 0.99
CREB gene transcription factors: role in molecular mechanisms of alcohol and drug addiction. Alcohol Clin Exp Res (2005) 0.98
Acute ethanol has biphasic effects on short- and long-term memory in both foreground and background contextual fear conditioning in C57BL/6 mice. Alcohol Clin Exp Res (2007) 0.98
Age-related impairment in the 250-millisecond delay eyeblink classical conditioning procedure in C57BL/6 mice. Learn Mem (2002) 0.97
The effects of acute, chronic, and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice. Psychopharmacology (Berl) (2011) 0.97
Hippocampal nAChRs mediate nicotine withdrawal-related learning deficits. Eur Neuropsychopharmacol (2009) 0.96
Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology (2007) 0.96
Differential distribution of CREB in the mesolimbic dopamine reward pathway. J Neurochem (2003) 0.96
Gadd45b knockout mice exhibit selective deficits in hippocampus-dependent long-term memory. Learn Mem (2012) 0.96
Behavioral and activity assessment of laboratory mice (Mus musculus) after tail biopsy under isoflurane anesthesia. J Am Assoc Lab Anim Sci (2011) 0.96
Associative learning, the hippocampus, and nicotine addiction. Curr Drug Abuse Rev (2008) 0.95
Nicotine withdrawal disrupts new contextual learning. Pharmacol Biochem Behav (2008) 0.95
Temporally dependent changes in cocaine-induced synaptic plasticity in the nucleus accumbens shell are reversed by D1-like dopamine receptor stimulation. Neuropsychopharmacology (2012) 0.94
The hippocampus and cingulate cortex differentially mediate the effects of nicotine on learning versus on ethanol-induced learning deficits through different effects at nicotinic receptors. Neuropsychopharmacology (2009) 0.94
Nicotinic receptors in the dorsal and ventral hippocampus differentially modulate contextual fear conditioning. Hippocampus (2012) 0.93
Extracellular signal-regulated kinase 1/2 involvement in the enhancement of contextual fear conditioning by nicotine. Behav Neurosci (2007) 0.93
Inducible cAMP early repressor regulates corticosterone suppression after tricyclic antidepressant treatment. J Neurosci (2004) 0.93
Augmented responses to morphine and cocaine in mice with a 12-lipoxygenase gene disruption. Psychopharmacology (Berl) (2003) 0.93
Involvement of hippocampal jun-N terminal kinase pathway in the enhancement of learning and memory by nicotine. Neuropsychopharmacology (2010) 0.92
Reversible inactivation of the entorhinal cortex disrupts the establishment and expression of latent inhibition of cued fear conditioning in C57BL/6 mice. Hippocampus (2007) 0.92
Nicotine withdrawal disrupts both foreground and background contextual fear conditioning but not pre-pulse inhibition of the acoustic startle response in C57BL/6 mice. Behav Brain Res (2008) 0.92
Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function. Hippocampus (2010) 0.92
Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology (2012) 0.92
Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus. Neuropharmacology (2010) 0.91
The interactive effects of nicotinic and muscarinic cholinergic receptor inhibition on fear conditioning in young and aged C57BL/6 mice. Pharmacol Biochem Behav (2004) 0.91
Genetic background influences the effects of withdrawal from chronic nicotine on learning and high-affinity nicotinic acetylcholine receptor binding in the dorsal and ventral hippocampus. Psychopharmacology (Berl) (2012) 0.90
Selective deletion of a cell cycle checkpoint kinase (ATR) reduces neurogenesis and alters responses in rodent models of behavioral affect. Neuropsychopharmacology (2011) 0.89
Differential effects of acute and repeated citalopram in mouse models of anxiety and depression. Int J Neuropsychopharmacol (2009) 0.89
Effects of ethanol and caffeine on behavior in C57BL/6 mice in the plus-maze discriminative avoidance task. Behav Neurosci (2009) 0.88
Cocaine-related behaviors in mice with deficient gliotransmission. Psychopharmacology (Berl) (2012) 0.88
Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology (2012) 0.88
Alterations in morphine-induced reward, locomotor activity, and thermoregulation in CREB-deficient mice. Brain Res (2005) 0.87
Regulation of antidepressant activity by cAMP response element binding proteins. Mol Neurobiol (2004) 0.87
Decreased CREB levels suppress epilepsy. Neurobiol Dis (2011) 0.86
Sex differences in response to nicotine in C57Bl/6:129SvEv mice. Nicotine Tob Res (2009) 0.86
Rolipram attenuates MK-801-induced deficits in latent inhibition. Behav Neurosci (2005) 0.86
Targeted deletion of the mouse α2 nicotinic acetylcholine receptor subunit gene (Chrna2) potentiates nicotine-modulated behaviors. J Neurosci (2013) 0.86
Effects of chronic low- and high-dose nicotine on cognitive flexibility in C57BL/6J mice. Behav Brain Res (2012) 0.86
The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. Behav Brain Res (2011) 0.85
Increased hippocampal neurogenesis and accelerated response to antidepressants in mice with specific deletion of CREB in the hippocampus: role of cAMP response-element modulator τ. J Neurosci (2013) 0.85
Malleability in the development of spatial reorientation. Dev Psychobiol (2012) 0.85
Of mice (Mus musculus) and toddlers (Homo sapiens): evidence for species-general spatial reorientation. J Comp Psychol (2009) 0.85
Parkinson's disease-like neuromuscular defects occur in prenyl diphosphate synthase subunit 2 (Pdss2) mutant mice. Mitochondrion (2011) 0.85
Depressive phenotypes evoked by experimental diabetes are reversed by insulin. Physiol Behav (2011) 0.84
Requirement for the POZ/BTB protein NAC1 in acute but not chronic psychomotor stimulant response. Behav Brain Res (2007) 0.83